A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT05785741. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors
Study identification
- NCT ID
- NCT05785741
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- DualityBio Inc.
- Industry
- Enrollment
- 1,000 participants
Conditions and interventions
Conditions
Interventions
- DB-1310 Drug
- Osimertinib Drug
- Trastuzumab Drug
- capecitabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 16, 2023
- Primary completion
- Dec 29, 2027
- Completion
- Apr 29, 2028
- Last update posted
- Apr 5, 2026
2023 – 2028
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Davis Comprehensive Cancer Center | Sacramento | California | 95817 | Recruiting |
| UCLA Hematology/Oncology - Santa Monica | Santa Monica | California | 90404 | Recruiting |
| Research Site 117 | Coral Gables | Florida | 33146 | Withdrawn |
| D&H Cancer Research Center LLC | Margate | Florida | 33063 | Withdrawn |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando | Florida | 32827 | Recruiting |
| BRCR global | Plantation | Florida | 33322 | Recruiting |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Recruiting |
| BRCR Medical Center Inc. | Tamarac | Florida | 33321 | Recruiting |
| Research Site 111 | Atlanta | Georgia | 30322 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Henry Ford Health System | Detroit | Michigan | 48202 | Recruiting |
| Research site 119 | Florham Park | New Jersey | 07932 | Active, not recruiting |
| Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center | Cincinnati | Ohio | 45219 | Recruiting |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | Recruiting |
| NEXT Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05785741, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05785741 live on ClinicalTrials.gov.